Cognition Therapeutics, Inc. Common Stock

CGTXNASDAQ • USD
ThemeBiotech - Drug Development›Neuroscience & CNS
1.29 USD
↘ 0.07 (5.15%)AT CLOSE (11:59 AM EDT)
1.36
↗ 0.07 (5.66%)
POST MARKET (AS OF 08:00 PM EDT)
Post Market
AS OF 08:00 PM EDT
1.36
↗ 0.07 (5.66%)
🔴Market: CLOSED
Open?$1.33
High?$1.33
Low?$1.22
Prev. Close?$1.36
Volume?1.1M
Avg. Volume?1.0M
VWAP?$1.29
Rel. Volume?1.11x
Bid / Ask
Bid?$1.08 × 100
Ask?$1.50 × 100
Spread?$0.42
Midpoint?$1.29
Valuation & Ratios
Market Cap?121.7M
Shares Out?89.5M
Float?79.6M
Float %?90.2%
P/E Ratio?N/A
P/B Ratio?4.07
EPS?-$0.22
Dividend?0.00%
Ex-Dividend?N/A

Cognition Therapeutics, Inc. Common Stock (CGTX) is currently trading at $1.29. There is a divergence between signals — technical indicators rate "Buy" but underlying fundamentals lean "Sell". This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. On valuation, CGTX trades roughly in line with sector averages — neither particularly cheap nor expensive.

Technical & fundamental data as of Jun 5, 2026.

News
Profile
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).
Themes
Biotech - Drug Development›Neuroscience & CNSLongevity & Aging›Age-Related Therapeutics
Employees
14
Market Cap
121.7M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
www.cogrx.com
Listed
2021-10-08
Address
2500 WESTCHESTER AVE
PURCHASE, NY 10577
Phone: 412-481-2210
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+1/3)
Medium-Term (Wave)?▲ Bullish(+2/3)
Short-Term (Ripple)?▼ Bearish(-2/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
10
Momentum?
77
Short Sent.?
54
Piotroski F-Score?0/9Weak
Altman Z-Score?0.93Distress
Confidence?42%Low
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?9.75%Elevated
Short Interest?7.8M
Days to Cover?9.7
Free Float79.6M
Avg Daily Volume804.1K
Settlement Date2026-05-15
Financial Health
Current Ratio?5.90Strong
Quick Ratio?5.90Strong
Cash Ratio?5.14Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
83/100
P/E?
N/A▾
P/B?
Peers
100
S&P
44
4.07FAIR▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-2.1CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
3
-65.5%WEAK▾
ROA?
S&P
3
-54.2%WEAK▾
Cash Flow & Enterprise
FCF?N/A
Enterprise Value?$90.6M
Fundamentals ratios updated end of day
MarketsMoversWatchlist